New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal, i.e. slowing of Alzheimer’s disease (AD) progression. However, antibody therapy may not be the optimal therapeutic modality for AD prevention, as we will discuss in the context of the earlier small molecules described as “γ-secretase modulators” (GSM). We review here the structure, function, and pathobiology of γ-secretases, with a focus on how mutations in presenilin genes result in early-onset AD. Significant progress has been made in generating compounds that act in a manner opposite to pathogenic presenilin mutations: they stabilize the proteinase-substrate complex, thereby increasing the processivity of substrate cleavage and altering the size spectrum of Aβ peptides produced. We propose the term “γ-secretase allosteric stabilizers” (GSAS) to distinguish these compounds from the rather heterogenous class of GSM. The GSAS represent, in theory, a precision medicine approach to the prevention of amyloid deposition, as they specifically target a discrete aspect in a complex cell biological signalling mechanism that initiates the pathological processes leading to Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [547]
The cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators of γ-secretase encourage the production of shorter, less toxic Aβ subtypes, and even potentially minimize effects on Notch and some other substrates. Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [547]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 161 · Cited by 36
Metadata
- Authors
- De Strooper, B., & Karran, E.
- Affiliations
- AbbVie (United States) (US)
- Venue
- The EMBO Journal
- Published
- 2024-02-23
- Volume
- 43
- Issue
- 6
- Pages
- 887-903
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC10943082
- OpenAlex
- W4392099111
- Cited by
- 36
- References
- 161
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 10
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- The EMBO Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- Lirias (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- The Francis Crick Institute (cc-by)
- Funders
- EC | European Research Council (ERC-834682)
- UK Research and Innovation (MR/Y014847/1)
- Fonds Wetenschappelijk Onderzoek
- Methusalem grant KULeuven
- Queen Elisabeth Medical Foundation for Neurosciences
- Belgian Alzheimer Research Foundation
- The Alzheimer’s Association USA
- Opening the Future
- Bax-Van Luffelen foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, gamma-secretase, γ-secretase modulators, presenilin mutations, early-onset Alzheimer's disease, amyloid-beta, amyloid deposition, anti-amyloid antibodies, precision medicine, Alzheimer's disease prevention
- MeSH terms
- Alzheimer Disease, Humans, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Presenilins, Presenilin-1, Amyloid Precursor Protein Secretases, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. https://app.cochat.ai/papers/10.1038/s44318-024-00057-w
- The paper
- De Strooper, B., & Karran, E. (2024). New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases. The EMBO Journal. https://doi.org/10.1038/s44318-024-00057-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.